KT-US-679-0788: A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma

Title
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma
Principal Investigator
Safi, Salah Ud Din
Phase
III
Age Group
Adult
Applicable Disease Sites
Multiple Myeloma
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Syed Abdul Mannan Shah
Clinical Research Specialist
Phone: +1 304-293-1683
Email:

View on ClinicalTrials.gov